Results Association of semaglutide with incident AUD diagnosis in patients with obesity and no prior history of AUD The study population consisted of 83,825 patients with obesity who had no prior diagnosis of AUD and were for the first time prescribed semaglutide or non-GLP-1RA anti-obesity medications including naltrexone or topiramate in 6/202112/2022
It is considered an appropriate adjunctive treatment option.[15,19] It seems to be a suitable method for rapid drug elimination and case reports of patients with severe amlodipine overdose refractory to aggressive medical therapy have described its use in successfully decreasing the levels of amlodipine and improving the patients hemodynamics until full recovery is made.[16,19,20] It seems to be most effective when initiated early and has been used as adjunctive therapy with other rescue therapies such as ECMO.[15,16,19] Other therapies Multiple other therapies have been proposed to help combat the cardiovascular collapse associated with amlodipine overdose
The region's market is growing, especially in the US and Canada, due to the presence of large pharmaceutical companies, favorable regulatory approvals, and the growing usage of GLP-1 receptor agonists for the treatment of obesity and diabetes
Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A1c, LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study
While it does involve recovery time and permanent scars, most patients find the trade-off well worth it for the improved comfort, function, and appearance they gain
